# Efficacy of RGn600 in Patients With Mild-to-moderate Alzheimer's Disease

> **NCT05926011** · NA · RECRUITING · sponsor: **REGEnLIFE SAS** · enrollment: 108 (estimated)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DEVICE:** RGn600
- **DEVICE:** RGn600 Sham

## Key facts

- **NCT ID:** NCT05926011
- **Lead sponsor:** REGEnLIFE SAS
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-24
- **Primary completion:** 2026-06
- **Final completion:** 2026-12
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2025-04-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05926011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05926011, "Efficacy of RGn600 in Patients With Mild-to-moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05926011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*